Retatrutide
Price range: $140.00 through $289.00
Retatrutide (LY3437943), a synthetic 39-residue peptide supplied as a lyophilised powder in 10 mg, 15 mg or 30 mg vials.
For laboratory research use only. Not for human or veterinary use. By ordering you confirm you are 18 or older and are purchasing for lawful research.
- Content per vial
- 10 mg, 15 mg or 30 mg
- Vial
- 3 mL vial
- Form
- Lyophilised powder
- Unopened, long term
- −20 °C, protected from light
Bacteriostatic water for the lab
Research peptides are supplied as a lyophilised powder. Bacteriostatic water is the standard laboratory solvent for reconstituting them, and ours is independently tested. For laboratory research use only.
Description
Retatrutide (development code LY3437943) is a synthetic 39-amino-acid peptide that has been studied as a single-molecule agonist at the GIP, GLP-1 and glucagon receptors.
Available in three vial sizes: 10 mg, 15 mg or 30 mg of Retatrutide, each supplied as a lyophilised powder in a 3 mL vial, intended for in-vitro and laboratory research. Choose the vial size above; each size has its own price, stock and independent lab report.
Research background
Retatrutide (development code LY3437943) was developed by Eli Lilly as a single peptide that acts as an agonist at three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It carries a fatty-acid side chain that binds serum albumin, a design used to extend a peptide's half-life. It is studied in metabolic and endocrine research.
Research stage: Investigational. Retatrutide has been evaluated in Phase 1 to Phase 3 clinical trials and is not approved by the TGA, the US FDA or any other regulator (as of October 2026).
Selected published research
- Coskun T, Urva S, Roell WC, et al. Cell Metab. 2022;34(9):1234-1247. PubMed 35985340
- Jastreboff AM, Kaplan LM, Frías JP, et al. N Engl J Med. 2023;389(6):514-526. PubMed 37366315
- Rosenstock J, Frias J, Jastreboff AM, et al. Lancet. 2023;402(10401):529-544. PubMed 37385280
- Jastreboff AM, Kaplan LM, Davies MJ, et al. N Engl J Med. 2026. PubMed 42814954
This section summarises the subject of published research for reference only. It does not describe the effects of this product, which is supplied for laboratory research use only and is not for human or veterinary use.
Background reading: Retatrutide (LY3437943): structure, identity testing and storage
Specifications
| Product | Retatrutide |
|---|---|
| SKU | APX-RET-10, APX-RET-15, APX-RET-30 |
| Category | Peptides |
| Content per vial | 10 mg, 15 mg or 30 mg |
| Vial | 3 mL vial |
| Form | Lyophilised powder |
| Synonyms | LY3437943 |
| Peptide length | 39 amino acids |
| Molecular formula | C221H342N46O68 |
| Molecular weight | ≈ 4731 g/mol |
| Intended use | Laboratory research only |
Storage
| Unopened, long term | −20 °C, protected from light |
|---|---|
| Unopened, short term | 2–8 °C for up to several weeks |
| After reconstitution | 2–8 °C; record the preparation date on the vial |
| Handling | Allow the vial to reach room temperature before opening to limit moisture uptake |
General guidance only. Follow your institution’s procedures for handling research materials.
Testing & COA
Each vial size is tested separately by Janoshik Analytical. Details below are transcribed from the reports; the PDFs are the authoritative copies.
10mg vial
| Laboratory | Janoshik Analytical |
|---|---|
| Task number | #232033 |
| Sample as recorded | reta10 |
| Tests requested | Common GLP-1 peptide blind test (Semaglutide, Tirzepatide and Retatrutide) |
| Result: Retatrutide | 11.97 mg; 11.93 mg; 11.91 mg |
| Purity | 99.596%; 99.572%; 99.483% |
| Batch on report | RE10-0901 |
| Sample received | 15 Sep 2026 |
| Analysis conducted | 16 Sep 2026 |
| Verification key | 5SMNRP3LMTI2 |
15mg vial
| Laboratory | Janoshik Analytical |
|---|---|
| Task number | #218225 |
| Sample as recorded | Retatrutide 15mg |
| Tests requested | Common GLP-1 peptide blind test (Semaglutide, Tirzepatide and Retatrutide) |
| Result: Retatrutide | 16.11 mg |
| Purity | 99.948% |
| Batch on report | Light bleu lids |
| Sample received | 07 Aug 2026 |
| Analysis conducted | 11 Aug 2026 |
| Verification key | 6YMKXHA2U868 |
30mg vial
| Laboratory | Janoshik Analytical |
|---|---|
| Task number | #96881 |
| Sample as recorded | Retatrutide 30mg |
| Tests requested | Assessment of a peptide vial or vials. |
| Result: Retatrutide | 30.62 mg |
| Purity | 99.795% |
| Batch on report | green cap, silver crimp |
| Sample received | 02 Jan 2026 |
| Analysis conducted | 07 Jan 2026 |
| Verification key | R3NDYIU7VZ6E |
Janoshik report #23203310mg vial, PDF
Janoshik report #21822515mg vial, PDF
Janoshik report #9688130mg vial, PDFCommon questions
How much is actually in the vial?
Each vial size has its own Janoshik Analytical report.
10mg vial: 11.97 mg; 11.93 mg; 11.91 mg Retatrutide, at 99.483%–99.596% purity (report #232033, 16 Sep 2026)
15mg vial: 16.11 mg Retatrutide, at 99.948% purity (report #218225, 11 Aug 2026)
30mg vial: 30.62 mg Retatrutide, at 99.795% purity (report #96881, 07 Jan 2026)
Measured amounts vary a little from batch to batch; the full results list everything each report covers.
How do I check the lab report is genuine?
Go to janoshik.com/verify and enter the key for your vial size. It brings up Janoshik's own record of the test, so you can confirm the PDF on this page matches what the laboratory issued.
10mg vial: 5SMNRP3LMTI2 (test #232033)
15mg vial: 6YMKXHA2U868 (test #218225)
30mg vial: R3NDYIU7VZ6E (test #96881)
What is it reconstituted with in the lab?
Retatrutide is supplied as a dry, lyophilised powder. In the laboratory, lyophilised peptides are usually reconstituted with bacteriostatic water, the standard laboratory solvent, which we stock in 3mL and 10mL vials (for laboratory research use only). See the storage notes above for unopened and reconstituted vials.
How long does shipping take in Australia?
Orders are dispatched within 1 business day of payment and sent by Australia Post Express Post with tracking, which usually arrives the next business day across most of the Express Post network (allow a few extra days for regional areas). Express Post is a $15 flat rate, or free on orders of $250 or more. We ship within Australia only. See the shipping policy.
How do I pay?
By PayID or bank transfer. The payment details appear as soon as you place your order and are emailed to you as well. Your order is dispatched once the payment arrives.
Disclaimer
Retatrutide (all vial sizes) is supplied for in-vitro and laboratory research only. It is not intended to diagnose, treat, cure or prevent any disease, and is not registered or listed on the Australian Register of Therapeutic Goods. Descriptions on this page summarise published chemical information and do not describe effects in humans or animals.
The purchaser is responsible for safe handling, storage and disposal, and for complying with all laws that apply to them. See the full Disclaimer and Research use terms.
datvinhtran1984 (verified owner) –
Great packaging, prompt delivery, and a professional presentation. The lab report is a nice touch, and everything arrived in excellent condition. Smooth experience overall!